公开(公告)号：WO2005054176A1

公开(公告)日：2005-06-16

申请号：PCT/US2004/035528

申请日：2004-11-16

Applicant: ELI LILLY AND COMPANY ,  CANADA, Emily, Jane ,  GOSSETT, Lynn, Stacy ,  MANTELO, Nathan, Bryan ,  SHI, Qing ,  WANG, Minmin ,  WARSHAWSKY, Alan, M. ,  XU, Yanping

Inventor： CANADA, Emily, Jane ,  GOSSETT, Lynn, Stacy ,  MANTELO, Nathan, Bryan ,  SHI, Qing ,  WANG, Minmin ,  WARSHAWSKY, Alan, M. ,  XU, Yanping

IPC: C07C233/73

CPC classification number: C07D213/81 ,  C07C211/29 ,  C07C233/73 ,  C07C235/46 ,  C07C235/48 ,  C07C235/54 ,  C07C235/84 ,  C07C271/16 ,  C07C311/04 ,  C07C311/17 ,  C07C317/44 ,  C07C323/62 ,  C07D209/30 ,  C07D209/42 ,  C07D213/56 ,  C07D333/70

Abstract: The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，溶剂合物水合物或立体异构体，其可用于治疗或预防由过氧化物酶体增殖物激活受体（PPAR）介导的病症，例如综合征X型 II型糖尿病，高血糖症，高脂血症，肥胖症，凝血病，高血压，动脉硬化以及与X综合症和心血管疾病有关的其他疾病。